Özet PDF Benzer Makaleler Yazara Mail Gönder

¹Süleyman Demirel Üniversitesi, Sağlık Yönetimi, Isparta, Türkiye DOI : 10.5137/1019-5157.TND.3269 Deep Brain Stimulation (DBS) has a significant impact on patients' quality of life in the treatment of Parkinson's disease (PD), the second most common neurodegenerative disease in the world after Alzheimer's. However, increasing budget constraints make it necessary to consider not only clinical effectiveness but also cost effectiveness in medical decision-making. The aim of this study is to conduct a systematic review on the cost-effectiveness of the DBS method in the treatment of PH. 12 articles selected according to PICOS criteria compare the DBS method with medication and medical device-assisted therapies (CDT). The majority of studies show that the additional cost-effectiveness ratio of DBS per QALY (Quality Adjusted Life Years) is below the threshold value. DBS treatment has a higher quality of life value compared to Medical Treatment (TT), but a lower quality of life value compared to other CDT. DBS is more costly than TT and more convenient than CDT. Additionally, sensitivity analyzes determined that battery life has a significant impact on maintaining the cost-effectiveness of DBS. In conclusion; DBS is more cost effective compared to TT. However, the scarcity of CDT studies makes it difficult to compare the three methods. Therefore, further research by impartial institutions is recommended. Anahtar Kelimeler : Deep brain stimulation, Cost-effectiveness analysis, Parkinsons disease, QALY